Klick Health



Read More

Sanofi is creating an app to help with depression for patients with MS. The company is working with Happify Health on the tool and is conducting proof of concept studies with several thousand MS patients before deciding whether to initiate a 510(k) certification.

The app is Sanofi’s first proposed digital therapeutic, and the company specifically chose MS as an entry point into the space because of its extensive experience with the condition, Ameet Nathwani, M.D., Sanofi’s chief medical officer and chief digital officer, said.

This is not planned as a one-off, either:

“This is a first foray, but we’re certainly talking to other companies about digital therapy approaches in other diseases. So yes, we see how this could become more of a portfolio play where we would have a portfolio of digital therapeutics which are clinically meaningful and could be used as prescribed agents,” he said.


Other stories from the Fierce network:



More About the Author

Klick Wire

This is the Klick Wire blog account. Here you will find archived versions of all your favorite Klick Wire stories. To get these stories delivered to your inbox every week, use the sign up form at the bottom of this page.

More from this author

Go from news to action. Klick Wire

Weekly Digital Health Newsletter

Klick Health will NEVER spam you. Read our privacy policy

Thank you! You're now signed up to get the Klick Wire every week - news from the world of digital health marketing.

Sorry there seems to be a problem. Please try again later.